Ganetespib: research and clinical development

di Jhaveri, Komal, Modi, Shanu
Pubblicato in Onco Targets Ther (2015)

HER2 breast cancer therapies: a review

di Murphy, Conleth G, Modi, Shanu
Pubblicazione 2009

Targeting the cyclin D–cyclin-dependent kinase (CDK)4/6–retinoblastoma pathway with selective CDK 4/6 inhibitors in hormone receptor-positive breast cancer: rationale, current stat...

di Spring, Laura, Bardia, Aditya, Modi, Shanu
Pubblicato in Discov Med (2016)

Unlocking the potential of antibody–drug conjugates for cancer therapy

di Drago, Joshua Z., Modi, Shanu, Chandarlapaty, Sarat
Pubblicato in Nat Rev Clin Oncol (2021)

Advances in the clinical development of heat shock protein 90 (Hsp90) inhibitors in cancers

di Jhaveri, Komal, Taldone, Tony, Modi, Shanu, Chiosis, Gabriela
Pubblicazione 2011

Advances in the discovery and development of heat-shock protein 90 inhibitors for cancer treatment

di Patel, Hardik J, Modi, Shanu, Chiosis, Gabriela, Taldone, Tony
Pubblicazione 2011

Chaperome heterogeneity and its implications for cancer study and treatment

di Wang, Tai, Rodina, Anna, Dunphy, Mark P., Corben, Adriana, Modi, Shanu, Guzman, Monica L., Gewirth, Daniel T., Chiosis, Gabriela
Pubblicato in J Biol Chem (2019)

Ex Vivo Treatment Response of Primary Tumors and/or Associated Metastases for Preclinical and Clinical Development of Therapeutics

di Corben, Adriana D., Uddin, Mohammad M., Crawford, Brooke, Farooq, Mohammad, Modi, Shanu, Gerecitano, John, Chiosis, Gabriela, Alpaugh, Mary L.
Pubblicato in J Vis Exp (2014)

Endocrine Therapy–Induced Alopecia in Patients With Breast Cancer

di Freites-Martinez, Azael, Shapiro, Jerry, Chan, Donald, Fornier, Monica, Modi, Shanu, Gajria, Devika, Dusza, Stephen, Goldfarb, Shari, Lacouture, Mario E.
Pubblicato in JAMA Dermatol (2018)

Phase 1b/2a study of trastuzumab emtansine (T-DM1), paclitaxel, and pertuzumab in HER2-positive metastatic breast cancer

di Krop, Ian E., Modi, Shanu, LoRusso, Patricia M., Pegram, Mark, Guardino, Ellie, Althaus, Betsy, Lu, Dan, Strasak, Alexander, Elias, Anthony
Pubblicato in Breast Cancer Res (2016)

The Effect of Molecular Subtype and Residual Disease on Locoregional Recurrence in Breast Cancer Patients Treated with Neoadjuvant Chemotherapy and Postmastectomy Radiation

di Yang, T. Jonathan, Morrow, Monica, Modi, Shanu, Zhang, Zhigang, Krause, Kate, Siu, Chun, McCormick, Beryl, Powell, Simon N., Ho, Alice Y.
Pubblicato in Ann Surg Oncol (2015)

A multicenter trial evaluating retaspimycin HCL (IPI-504) plus trastuzumab in patients with advanced or metastatic HER2-positive breast cancer

di Modi, Shanu, Saura, Cristina, Henderson, Charles, Lin, Nancy U., Mahtani, Reshma, Goddard, Jill, Rodenas, Eduardo, Hudis, Clifford, O’Shaughnessy, Joyce, Baselga, Jose
Pubblicazione 2013

Phase II Study of Weekly Paclitaxel with Trastuzumab and Pertuzumab in Patients with Human Epidermal Growth Receptor 2 Overexpressing Metastatic Breast Cancer: 5‐Year Follow‐up

di Wang, Rui, Smyth, Lillian M., Iyengar, Neil, Chandarlapaty, Sarat, Modi, Shanu, Jochelson, Maxine, Patil, Sujata, Norton, Larry, Hudis, Clifford A., Dang, Chau T.
Pubblicato in Oncologist (2019)

Frequent mutational activation of the PI3K-AKT pathway in trastuzumab-resistant breast cancer

di Chandarlapaty, Sarat, Sakr, Rita A., Giri, Dilip, Patil, Sujata, Heguy, Adriana, Morrow, Monica, Modi, Shanu, Norton, Larry, Rosen, Neal, Hudis, Clifford, King, Tari A.
Pubblicazione 2012

Increased levels of urinary PGE-M, a biomarker of inflammation, occur in association with obesity, aging and lung metastases in patients with breast cancer

di Morris, Patrick G., Zhou, Xi Kathy, Milne, Ginger L., Goldstein, Daniel, Hawks, Laura C., Dang, Chau T., Modi, Shanu, Fornier, Monica N., Hudis, Clifford A., Dannenberg, Andrew J.
Pubblicazione 2013

A Phase I study of alpelisib in combination with trastuzumab and LJM716 in patients with PIK3CA-mutated HER2-positive metastatic breast cancer

di Jhaveri, Komal, Drago, Joshua Z., Shah, Payal Deepak, Wang, Rui, Pareja, Fresia, Ratzon, Fanni, Iasonos, Alexia, Patil, Sujata, Rosen, Neal, Fornier, Monica N., Sklarin, Nancy T., Chandarlapaty, Sarat, Modi, Shanu
Pubblicato in Clin Cancer Res (2021)

Assessment of Quality of Life and Treatment Outcomes of Patients With Persistent Postchemotherapy Alopecia

di Freites-Martinez, Azael, Chan, Donald, Sibaud, Vincent, Shapiro, Jerry, Fabbrocini, Gabriella, Tosti, Antonella, Cho, Juhee, Goldfarb, Shari, Modi, Shanu, Gajria, Devika, Norton, Larry, Paus, Ralf, Cigler, Tessa, Lacouture, Mario E.
Pubblicato in JAMA Dermatol (2019)

Heat shock protein 90 inhibitors in the treatment of cancer: current status and future directions

di Jhaveri, Komal, Ochiana, Stefan O, Dunphy, Mark PS, Gerecitano, John F, Corben, Adriana D, Peter, Radu I, Janjigian, Yelena Y, Gomes-DaGama, Erica M, Koren, John, Modi, Shanu, Chiosis, Gabriela
Pubblicazione 2014

Biomarkers that Predict Sensitivity to Heat Shock Protein 90 Inhibitors (HSP90i)

di Jhaveri, Komal, Chandarlapaty, Sarat, Iyengar, Neil, Morris, Patrick G., Corben, Adriana D, Patil, Sujata, Akram, Muzaffar, Towers, Russell, Sakr, Rita A, King, Tari A, Norton, Larry, Rosen, Neal, Hudis, Clifford, Modi, Shanu
Pubblicato in Clin Breast Cancer (2015)

Pilot study of (68)Ga-DOTA-F(ab′)(2)-trastuzumab in patients with breast cancer

di Beylergil, Volkan, Morris, Patrick G., Smith-Jones, Peter M., Modi, Shanu, Solit, David, Hudis, Clifford A., Lu, Yang, O’Donoghue, Joseph, Lyashchenko, Serge K., Carrasquillo, Jorge A., Larson, Steven M., Akhurst, Timothy J.
Pubblicazione 2013